aTyr Pharma, Inc. (LIFE)

Insurance Agents, Brokers & Service · market cap $352M · as of 2026-07-09

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

aTyr Pharma (LIFE) is a clinical-stage biotech with a $352M market cap and $107.9M in cash, developing efzofitimod as its lead asset in a Phase 3 trial for pulmonary sarcoidosis. The pipeline also includes ATYR1940 in Phase 2 for limb-girdle muscular dystrophies and efzofitimod in Phase 2 for interstitial lung disease and severe COVID-19 pneumonia. No upcoming catalysts are currently calendared, and insider selling activity over the past 90 days is notable.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
ATYR1940	Phase 2	Limb-Girdle Muscular Dystrophies
efzofitimod 450 mg	Phase 2	Interstitial Lung Disease
Efzofitimod 3 mg/kg	Phase 3	Pulmonary Sarcoidosis
Efzofitimod 1 mg/kg	Phase 2	SARS-CoV-2 (COVID-19) Severe Pneumonia

Price & technical context

3-month

+79.4%

6-month

—

12-month

—

52-wk range

$9.85–$30.59

vs 50-day MA

-3.9%

vs 200-day MA

—

Realized vol

101.8%

Max drawdown

-50.1%

Daily closes through 2026-06-24. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for LIFE (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.